Experimental eye injection aims to slow vision loss in rare disease

NCT ID NCT06292650

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage trial tests the safety of a new drug called ZM-02, given as an injection into one eye, in 12 adults with retinitis pigmentosa—a genetic condition that causes gradual vision loss. The main goal is to check for side effects, not to cure the disease. Researchers will also measure if the injection helps patients see better in dim light.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RETINITIS PIGMENTOSA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Beijing Tongren Hospital of Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.